Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD
 

Professor of Medical Oncology
Director, Yonsei Song-Dang Institute for Cancer Research
Yonsei University College of Medicine
Seoul, Korea

In the current environment of precision treatments for cancer, what kind of genetic alterations can be categorized as actionable? What other criteria would make a genetic alteration actionable? Video

In the current environment of precision treatments for cancer, what kind of genetic alterations can be categorized as actionable? What other criteria would make a genetic alteration actionable?

In the current environment of precision treatments for cancer, what kind of genetic alterations can be categorized as actionable? For example, if the mutation is linked to an approved therapy in the solid tumor under study or another solid ...
Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD

The current FoundationOne assay examines about 315 genes known to be somatically altered in human solid tumors, as well as 28 translocations. How were these genes determined? What makes them significant? Video

The current FoundationOne assay examines about 315 genes known to be somatically altered in human solid tumors, as well as 28 translocations. How were these genes determined? What makes them significant?

The current FoundationOne assay examines about 315 genes known to be somatically altered in human solid tumors, as well as 28 translocations. How were these genes determined? What makes them significant?
Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD

Why are current genomic testing models based on targeted sequencing ("Hot Spot") unsustainable and less effective than comprehensive genomic profiling (CGP) developed by FoundationOne? Video

Why are current genomic testing models based on targeted sequencing ("Hot Spot") unsustainable and less effective than comprehensive genomic profiling (CGP) developed by FoundationOne?

Why are current genomic testing models based on targeted sequencing (“Hot Spot”) unsustainable and less effective than comprehensive genomic profiling (CGP) developed by FoundationOne?
Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD

What is the overall accuracy and reproducibility rate for cancer genomic profiling based on massively parallel DNA sequencing? At what point in the disease process should CGP be employed? Video

What is the overall accuracy and reproducibility rate for cancer genomic profiling based on massively parallel DNA sequencing? At what point in the disease process should CGP be employed?

What is the overall accuracy and reproducibility rate for cancer genomic profiling based on massively parallel DNA sequencing? And at what point in the cancer disease process should CGP be employed?
Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD

How do you select patients with solid tumors that are appropriate for NGS? Is it just for patients who present with cancer? For patients under treatment? For assessment of tumors in relapsed patients? Video

How do you select patients with solid tumors that are appropriate for NGS? Is it just for patients who present with cancer? For patients under treatment? For assessment of tumors in relapsed patients?

How do you select patients with solid tumors that are appropriate for NGS? Is it useful just for patients with cancer at time of presentation? Can it be used for patients under treatment? For assessment of tumors in patients who have relapsed?
Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD

How does the FoundationOne CGP improve the power of its test to detect an alteration that is present in only some, but not all, of the tumor cells? Video

How does the FoundationOne CGP improve the power of its test to detect an alteration that is present in only some, but not all, of the tumor cells?

How does the FoundationOne CGP improve the power of its test to detect an alteration that is present in only some, but not all, of the tumor cells?
Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD

How well do other non-F1M methods for NGS assessment work? Are they as effective? Highly aggressive or resistant tumors? Cancers of unknown primary? Cancers with limited tissue samples? Video

How well do other non-F1M methods for NGS assessment work? Are they as effective? Highly aggressive or resistant tumors? Cancers of unknown primary? Cancers with limited tissue samples?

How well do other non-F1M methods for NGS assessment work? Are they as effective? Why or why not? Highly aggressive or resistant tumors? Cancers of unknown primary? Cancers with limited tissue samples? Please explain.
Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD

What common mutations and rearrangements--among them EGFR, ALK, HER2, BRAF, RAS, MET, RET and ROS-- present in tumors represent the best molecular targets for cancer therapy? Video

What common mutations and rearrangements--among them EGFR, ALK, HER2, BRAF, RAS, MET, RET and ROS-- present in tumors represent the best molecular targets for cancer therapy?

What common mutations and rearrangements—among them EGFR, ALK, HER2, BRAF, RAS, MET, RET and ROS— present in tumors represent the best molecular targets for cancer therapy? Are some more predictive of success with targeted therapy than others? Why?
Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD

What guidance can you give when the F1M CGP profile reveals multiple actionable mutations? Why select targeted therapies when multiple genomic alterations or rearrangements co-exist? Video

What guidance can you give when the F1M CGP profile reveals multiple actionable mutations? Why select targeted therapies when multiple genomic alterations or rearrangements co-exist?

What guidance can you give in those cases in which the F1M CGP profile reveals multiple actionable mutations? On what basis would you select targeted therapies when multiple significant genomic alterations or rearrangements co-exist?
Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD

What is the evidence that personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve outcomes? Video

What is the evidence that personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve outcomes?

What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient’s disease are aligned with specific therapy, will improve patient outcomes? To what extent are they improved with ...
Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD

For what solid tumors and hematologic malignancies has NGS genomic profiling shown to be most valuable for identifying disease alleles which can reliably guide the use of molecularly targeted therapy? Video

For what solid tumors and hematologic malignancies has NGS genomic profiling shown to be most valuable for identifying disease alleles which can reliably guide the use of molecularly targeted therapy?

For what specific solid tumors and hematologic malignancies has NGS genomic profiling shown to be most valuable for identifying disease alleles which can reliably guide the use of molecularly targeted therapy?
Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD